Under RFK Jr.'s leadership, the FDA has proposed an Interim Access Policy granting enforcement discretion for certain unproven peptide drugs, despite agency scientists previously flagging inadequate safety and efficacy data. The move comes as these peptides have gained popularity in the MAHA movement with unsubstantiated wellness claims.
Background
RFK Jr. became U.S. Health Secretary and has promoted the Make America Healthy Again (MAHA) movement, often advocating for alternative health approaches. The FDA has historically required compounding pharmacies to meet strict standards for drug safety and efficacy.
- Source
- Ars Technica
- Published
- Oct 17, 2026 at 01:05 AM
- Score
- 7.0 / 10